VIVUS (VVUS) Higher as Qsymia Prescriptions Show Confident Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
VIVUS (VVUS) Qsymia Prescriptions Remain High Amid Birth Defect Warning; Positive for Arena (ARNA)
October 26, 2012 11:58 AM EDTVIVUS (Nasdaq: VVUS) Qsymia is gaining more and more traction, according to the latest data from Bloomberg Industries and Healthcare Analytics.
According to the data, Qsymia prescriptions were up 30 percent from the prior week, with over 700 physicians prescribing the obesity pill. Of the... More
VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two
October 8, 2012 12:48 PM EDTVIVUS (Nasdaq: VVUS) shares are higher on the session following improving payment metrics for its obesity drug Qsymia.
According to Bloomberg Industries, Qsymia's prescription insurer payment rate rose 5 points in its second week to 36 percent.
Initial estimates from the company... More
